SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets Adds Report: PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 [Professional Services Close - Up]

[March 03, 2014]

Research and Markets Adds Report: PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 [Professional Services Close - Up]

(Professional Services Close - Up Via Acquire Media NewsEdge) Research and Markets has announced the addition of the "PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022" report to its offerings.


In a release, Research and Markets noted that report highlights include: The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The currently marketed product with the highest growth rate over the forecast period will be Regeneron/Bayer's Eylea. Even though the drug is still in the pipeline for DME, it is being used off-label already. Its usage will drastically increase upon its approval for the DME indication in 2014; however, it might meet some reimbursement opposition in Germany and apply a more aggressive pricing strategy.

Scope - Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Germany from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the Germany MCD market.

Key Topics Covered 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix Research and Markets is a source for international market research reports and market data.

Report information: www.researchandmarkets.com/research/n4xnsb/pharmapoint ((Comments on this story may be sent to newsdesk@closeupmedia.com)) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved.

[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.